Scholar Rock - SRRK Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings or view top-rated stocks.

5 analysts have issued 1-year price objectives for Scholar Rock's shares. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they predict the company's share price to reach $25.67 in the next year. This suggests a possible upside of 179.3% from the stock's current price.
View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts.

Scholar Rock's stock was trading at $9.05 at the beginning of 2023. Since then, SRRK shares have increased by 1.5% and is now trading at $9.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our SRRK earnings forecast.

Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings data on Tuesday, March, 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.11. During the same quarter last year, the firm earned ($0.97) EPS.

ETFs with the largest weight of Scholar Rock (NASDAQ:SRRK) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Scholar Rock's stock is owned by many different institutional and retail investors. Top institutional investors include Artal Group S.A. (17.38%), Price T Rowe Associates Inc. MD (13.62%), T. Rowe Price Investment Management Inc. (4.77%), Bank of America Corp DE (2.03%), Geode Capital Management LLC (0.70%) and Morgan Stanley (0.59%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman and Public Equities LP Invus.
View institutional ownership trends.

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRRK stock can currently be purchased for approximately $9.19.

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $477.79 million and generates $33.19 million in revenue each year. The company earns $-134,500,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

The company employs 145 workers across the globe.

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.